The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next two to three months.
Related Posts
Stock futures tick lower as investors await Federal Reserve’s interest rate decision: Live updates
The Federal Reserve is poised to make its first decision on interest rates in 2025.
Stablecoin issuer Circle kicks off its IPO, targeting a nearly $6 billion valuation
Circle, the issuer of the popular USDC stablecoin, has launched its initial public offering, looking to raise about $624 million at a $5.65 billion valuation.
IBM is a buy that’s poised to rally nearly 30%, Oppenheimer says
Investors are currently underappreciating IBM’s pivot to software, according to Oppenheimer.